Accelerated drug approval: Meeting the ethical yardstick
Drugs addressing unmet medical needs can change the lives of millions. Developing and validating new drugs can, however, take many years. To streamline the assessment of new drugs, regulatory agencies have long established shortened review pathways. Among these programs, Accelerated Approval (AA) ha...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley-Blackwell
2023
|
| In: |
Bioethics
Year: 2023, Volume: 37, Issue: 7, Pages: 647-655 |
| IxTheo Classification: | KBQ North America NCH Medical ethics NCJ Ethics of science XA Law |
| Further subjects: | B
drug regulation
B Aducanumab B Accelerated Approval B ethics of clinical research |
| Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1854423754 | ||
| 003 | DE-627 | ||
| 005 | 20230815141332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230805s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bioe.13191 |2 doi | |
| 035 | |a (DE-627)1854423754 | ||
| 035 | |a (DE-599)KXP1854423754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Andreoletti, Mattia |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Accelerated drug approval: Meeting the ethical yardstick |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Drugs addressing unmet medical needs can change the lives of millions. Developing and validating new drugs can, however, take many years. To streamline the assessment of new drugs, regulatory agencies have long established shortened review pathways. Among these programs, Accelerated Approval (AA) has recently come under scrutiny due to the U.S. Food and Drug Administration's decision to authorize Aducanumab, the first Alzheimer's disease drug. This decision attracted fierce criticism due to the allegedly insufficient evidence about the safety and efficacy of the drug. While considerable scholarly attention has been devoted to this case, the ethical aspects of the AA regulatory pathway have so far remained relatively unexplored. In this paper, we set out to fill this gap. We illustrate six conditions that should be met for AA to be ethically acceptable: moral solicitude, evidence, risk mitigation, impartiality, sustainability, and transparency. We discuss such conditions and suggest practical steps to implement them in regulatory and oversight processes. Taken together, our six conditions represent a benchmark for assessing the ethical validity of AA processes and decisions. | ||
| 650 | 4 | |a ethics of clinical research | |
| 650 | 4 | |a drug regulation | |
| 650 | 4 | |a Aducanumab | |
| 650 | 4 | |a Accelerated Approval | |
| 652 | |a KBQ:NCH:NCJ:XA | ||
| 700 | 1 | |a Blasimme, Alessandro |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioethics |d Oxford [u.a.] : Wiley-Blackwell, 1987 |g 37(2023), 7, Seite 647-655 |h Online-Ressource |w (DE-627)271596708 |w (DE-600)1480658-7 |w (DE-576)078707986 |x 1467-8519 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:7 |g pages:647-655 |
| 856 | |u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bioe.13191 |x unpaywall |z Vermutlich kostenfreier Zugang |h publisher [open (via crossref license)] | ||
| 856 | 4 | 0 | |u https://doi.org/10.1111/bioe.13191 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.13191 |x Verlag |z kostenfrei |3 Volltext |
| 935 | |a mteo | ||
| 936 | u | w | |d 37 |j 2023 |e 7 |h 647-655 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4363269294 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1854423754 | ||
| LOK | |0 005 20230815141332 | ||
| LOK | |0 008 230805||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2023-08-04#5DFE04616226812DCD5997ACC4E6DB7271F74A94 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a zota | ||
| LOK | |0 936ln |0 1550736558 |a NCH | ||
| LOK | |0 936ln |0 1550736582 |a NCJ | ||
| LOK | |0 936ln |0 1442049227 |a KBQ | ||
| LOK | |0 936ln |0 1442053798 |a XA | ||
| OAS | |a 1 | ||
| ORI | |a TA-MARC-ixtheoa001.raw | ||
| REL | |a 1 | ||
| SUB | |a REL | ||